PALO ALTO, Calif., May 8 /PRNewswire/ -- Anacor Pharmaceuticals
announced today that it will present six posters on topical
anti-inflammatory candidates, AN2728 and AN2898, at the upcoming
International Investigative Dermatology 2008 Conference, taking place May
14-17, 2008 in Kyoto, Japan. The IID Conference is the Fifth Joint Meeting
of the European Society for Dermatological Research (ESDR), the Japanese
Society for Investigative Dermatology (JSID) and the Society for
Investigative Dermatology (SID).
Poster Session 1: Friday May 16, 5:30-7 p.m.
Poster title (#89): In vitro activity and mechanism of action of AN2728,
a novel oxaborole in development for treatment of psoriasis
Poster title (#367): AN2728, a novel oxaborole in development for
treatment of psoriasis, demonstrates significant activity in a micro
Poster Session 2: Saturday May 17, 1:15-2:45 p.m.
Poster title (#84): Preclinical toxicology of AN2728, a novel oxaborole
in development for the topical treatment of psoriasis
Poster title (#86): AN2898, a novel oxaborale compound with
anti-inflammatory activity: mechanism of action and in vitro cytokine
Poster title (#88): Structure-activity studies of AN2728 and AN2898,
novel oxaborole compounds with anti-inflammatory activities
Poster title (#90): AN2898, a novel oxaborale compound with
anti-inflammatory activity: results of in vivo efficacy and preclinical
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. Anacor entered into a worldwide license, development and commercialization agreement for AN2690 with Schering-Plough for all indications including the treatment of onychomycosis. Anacor also has a research and development collaboration with GlaxoSmithKline for the discovery, development, manufacture and worldwide commercialization of novel systemic therapeutics for viral and bacterial diseases utilizing Anacor's boron-based chemistry. For more information visit http://www.anacor.com.
This press release contains forward-looking statements, including statements regarding the progress of our clinical trials and the safety and efficacy of our product candidates. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. Some factors that may affect these forward-looking statements include, but are not limited to, delays in the completion of our clinical trials, clinical failure at later stages of development and undesirable effects from our product candidates. These statements reflect the views of Anacor as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
|SOURCE Anacor Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved